Immatics Announces Third Quarter 2020 Financial Results and Business Update
- ACTengine® IMA200 clinical trial series continues scaling globally; initial analysis for patients in ACTengine® dose escalation is on track for Q1 2021
- Expansion of UTHealth partnership secures cell therapy manufacturing capacities until end of 2024
- Positive pre-clinical data updates on ACTengine® IMA204 and first TCR Bispecifics (TCER™) program IMA401
- Strengthened leadership team with appointment of Arnd Christ as Chief Financial Officer and addition of Eliot Forster to Immatics’ Board of Directors
- Cash and cash equivalents as well as other financial assets of €259.3 million ($303.6 million1) as of September 30, 2020 provide cash reach into 2023
Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported financial results and provided a business update for the quarter ended September 30, 2020.